View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
February 15, 2019updated 12 Jul 2022 1:08pm

Merck plans Phase III trials for Keytruda in prostate cancer

Merck has announced plans to launch three pivotal Phase III clinical trials for its immunotherapy Keytruda as a combination treatment for prostate cancer after the drug demonstrated anti-tumour activity in an early-stage trial.

Merck has announced plans to launch three pivotal Phase III clinical trials for its immunotherapy Keytruda as a combination treatment for prostate cancer after the drug demonstrated anti-tumour activity in an early-stage trial.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Keytruda showed activity when given in conjunction with various other agents to patients with metastatic castration-resistant prostate cancer (mCRPC) in the Phase Ib/II KEYNOTE-365 trial.

The 400-patient umbrella trial involved combinations with Lynparza, enzalutamide, docetaxel and prednisone. The safety profile of the combinations was observed to be consistent with that of the individual agents.

Merck Research Laboratories senior vice-president Roy Baynes said: “At the core of our research program is a commitment to investigate the potential of Keytruda, both as combination and monotherapy, to serve as a foundational treatment, especially for cancers where additional therapies are needed.

“At the core of our research program is a commitment to investigate the potential of Keytruda, both as combination and monotherapy.”

“These promising data presented at ASCO GU coupled with the significant unmet medical need in patients with metastatic castration-resistant prostate cancer, propelled us to initiate three new Phase III trials to further evaluate these KEYTRUDA combination regimens.”

One of the new Phase III trials, KEYLYNK-010, will assess the safety and efficacy of Keytruda and Lynparza combination in 780 mCRPC patients.

The trial is scheduled to begin in May this year and is expected to be concluded by September 2022.

Meanwhile, the randomised, double-blind KEYNOTE-921 trial will study Keytruda in combination with docetaxel and prednisone in a total of 1,000 participants.

KEYNOTE-921 is set to be completed in February 2023.

Merck will also study Keytruda plus enzalutamide in the third KEYNOTE-641 trial involving 1,200 participants. Scheduled to be initiated in July this year, this trial will be completed by April 2024.

Currently, the drug is being evaluated for prostate cancer in multiple trials, including Phase II KEYNOTE-199 and Phase III PROfound and PROPEL trials.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena